191 related articles for article (PubMed ID: 29928355)
1. Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21.
Jing C; Cao H; Qin X; Yu S; Wu J; Wang Z; Ma R; Feng J
Oncol Lett; 2018 Jun; 15(6):9811-9817. PubMed ID: 29928355
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
3. Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer.
Zhang Y; Li M; Hu C
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):457-464. PubMed ID: 30458987
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
7. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway.
Sun XH; Wang X; Zhang Y; Hui J
Thromb Res; 2019 May; 177():23-32. PubMed ID: 30844685
[TBL] [Abstract][Full Text] [Related]
8. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
9. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract][Full Text] [Related]
10. MiR-153 inhibits the resistance of lung cancer to gefitinib via modulating expression of ABCE1.
Wang L; Lv X; Fu X; Su L; Yang T; Xu P
Cancer Biomark; 2019; 25(4):361-369. PubMed ID: 31306106
[TBL] [Abstract][Full Text] [Related]
11. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
12. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
13. Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC.
Yu Y; Abudula M; Li C; Chen Z; Zhang Y; Chen Y
Respir Res; 2019 Oct; 20(1):217. PubMed ID: 31606039
[TBL] [Abstract][Full Text] [Related]
14. Exosome-derived circKIF20B suppresses gefitinib resistance and cell proliferation in non-small cell lung cancer.
Wei SL; Ye JJ; Sun L; Hu L; Wei YY; Zhang DW; Xu MM; Fei GH
Cancer Cell Int; 2023 Jul; 23(1):129. PubMed ID: 37394466
[TBL] [Abstract][Full Text] [Related]
15. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
16. Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.
Li XQ; Liu JT; Fan LL; Liu Y; Cheng L; Wang F; Yu HQ; Gao J; Wei W; Wang H; Sun GP
Oncotarget; 2016 Apr; 7(17):24585-95. PubMed ID: 27029054
[TBL] [Abstract][Full Text] [Related]
17. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
[TBL] [Abstract][Full Text] [Related]
18. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
19. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.
Liu Z; Yao L; Tan B; Li L; Chen B
Oncol Lett; 2016 Dec; 12(6):5349-5355. PubMed ID: 28101246
[TBL] [Abstract][Full Text] [Related]
20. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
